Marksans Pharma Quarterly Results for Trading Insights
In Mar 2026, Marksans Pharma (MARKSANS) reported revenue ₹891 Cr and net profit ₹149 Cr — revenue +23.1% YoY. For annual financials, live price and key ratios, visit MARKSANS share price screener.
MARKSANS Quarterly Results — Revenue, Profit & EPS Highlights
Marksans Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore Marksans Pharma share price performance to track price trends across different timeframes.
- Revenue of ₹891 Cr in Mar 2026 (+20.1% vs Sept 2025, +23.1% vs Mar 2025)
- Net Profit of ₹149 Cr in Mar 2026 (+50.5% vs Sept 2025, +63.7% vs Mar 2025)
- EBITDA of ₹231 Cr in Mar 2026 (+39.2% vs Sept 2025)
- Operating Margin of 23.0% in Mar 2026 (+3.0pp vs Sept 2025)
- Earnings Per Share of ₹3.27 in Mar 2026 (+50.7% vs Sept 2025)
Marksans Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
MARKSANS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 891 | 742 | 724 | 626 | 775 | 20.1% | 23.1% |
| Net Profit (₹ Cr) | 149 | 99 | 91 | 58 | 114 | - | - |
| EBITDA (₹ Cr) | 231 | 166 | 142 | 106 | 181 | - | - |
| EPS (₹) | 3.27 | 2.17 | 2.00 | 1.29 | 2.50 | - | - |
| Operating Margin (%) | 23.0% | 20.0% | 18.0% | 16.0% | 21.0% | - | - |
MARKSANS Share Price Trend — 1-Year Movement Across Quarterly Results
Marksans Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Browse MARKSANS financial statements for revenue, profit, balance sheet and cash flow data.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
MARKSANS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Marksans Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹469,405.89 Cr | 1941.1 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 171.8 |
|
Divis Laboratories
Mar 2026 |
₹194,269.91 Cr | 7248.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 256.0 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹191,454.40 Cr | 4961.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.1 |
|
Zydus Life Science
Mar 2026 |
₹115,616.29 Cr | 1108.7 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 87.6 |
|
Cipla
Mar 2026 |
₹114,318.19 Cr | 1410.6 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 205.3 |
All amounts in ₹ Crores